Cargando…
Profile of pembrolizumab in the treatment of head and neck squamous cell carcinoma: design development and place in therapy
Head and neck squamous cell cancer (HNSCC) is the sixth most common malignancy worldwide, and despite advances in cytotoxic, surgical and radiation techniques, outcomes are still poor in those with both locally advanced and metastatic diseases. The need for development of better therapeutics along w...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5587117/ https://www.ncbi.nlm.nih.gov/pubmed/28919706 http://dx.doi.org/10.2147/DDDT.S119537 |
_version_ | 1783261941017346048 |
---|---|
author | Haque, Sulsal Yellu, Mahender Randhawa, Jaskirat Hashemi-Sadraei, Nooshin |
author_facet | Haque, Sulsal Yellu, Mahender Randhawa, Jaskirat Hashemi-Sadraei, Nooshin |
author_sort | Haque, Sulsal |
collection | PubMed |
description | Head and neck squamous cell cancer (HNSCC) is the sixth most common malignancy worldwide, and despite advances in cytotoxic, surgical and radiation techniques, outcomes are still poor in those with both locally advanced and metastatic diseases. The need for development of better therapeutics along with a greater understanding of the relationship between the immune system and malignancies has led to a new therapeutic modality, immune modulators, particularly checkpoint inhibitors in HNSCC. It is now well recognized that HNSCC circumvents crucial pathways utilized by the immune system to escape surveillance. These hijacked pathways include impairing tumor antigen presentation machinery and co-opting checkpoint receptors. This understanding has led to the development of monoclonal antibodies targeting checkpoint receptors and has resulted in promising outcomes in HNSCC. This article describes the mechanisms that HNSCC utilizes to escape immune surveillance, clinical impact of checkpoint inhibitors (with a focus on pembrolizumab), ongoing studies, and future directions. |
format | Online Article Text |
id | pubmed-5587117 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-55871172017-09-15 Profile of pembrolizumab in the treatment of head and neck squamous cell carcinoma: design development and place in therapy Haque, Sulsal Yellu, Mahender Randhawa, Jaskirat Hashemi-Sadraei, Nooshin Drug Des Devel Ther Review Head and neck squamous cell cancer (HNSCC) is the sixth most common malignancy worldwide, and despite advances in cytotoxic, surgical and radiation techniques, outcomes are still poor in those with both locally advanced and metastatic diseases. The need for development of better therapeutics along with a greater understanding of the relationship between the immune system and malignancies has led to a new therapeutic modality, immune modulators, particularly checkpoint inhibitors in HNSCC. It is now well recognized that HNSCC circumvents crucial pathways utilized by the immune system to escape surveillance. These hijacked pathways include impairing tumor antigen presentation machinery and co-opting checkpoint receptors. This understanding has led to the development of monoclonal antibodies targeting checkpoint receptors and has resulted in promising outcomes in HNSCC. This article describes the mechanisms that HNSCC utilizes to escape immune surveillance, clinical impact of checkpoint inhibitors (with a focus on pembrolizumab), ongoing studies, and future directions. Dove Medical Press 2017-08-31 /pmc/articles/PMC5587117/ /pubmed/28919706 http://dx.doi.org/10.2147/DDDT.S119537 Text en © 2017 Haque et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Review Haque, Sulsal Yellu, Mahender Randhawa, Jaskirat Hashemi-Sadraei, Nooshin Profile of pembrolizumab in the treatment of head and neck squamous cell carcinoma: design development and place in therapy |
title | Profile of pembrolizumab in the treatment of head and neck squamous cell carcinoma: design development and place in therapy |
title_full | Profile of pembrolizumab in the treatment of head and neck squamous cell carcinoma: design development and place in therapy |
title_fullStr | Profile of pembrolizumab in the treatment of head and neck squamous cell carcinoma: design development and place in therapy |
title_full_unstemmed | Profile of pembrolizumab in the treatment of head and neck squamous cell carcinoma: design development and place in therapy |
title_short | Profile of pembrolizumab in the treatment of head and neck squamous cell carcinoma: design development and place in therapy |
title_sort | profile of pembrolizumab in the treatment of head and neck squamous cell carcinoma: design development and place in therapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5587117/ https://www.ncbi.nlm.nih.gov/pubmed/28919706 http://dx.doi.org/10.2147/DDDT.S119537 |
work_keys_str_mv | AT haquesulsal profileofpembrolizumabinthetreatmentofheadandnecksquamouscellcarcinomadesigndevelopmentandplaceintherapy AT yellumahender profileofpembrolizumabinthetreatmentofheadandnecksquamouscellcarcinomadesigndevelopmentandplaceintherapy AT randhawajaskirat profileofpembrolizumabinthetreatmentofheadandnecksquamouscellcarcinomadesigndevelopmentandplaceintherapy AT hashemisadraeinooshin profileofpembrolizumabinthetreatmentofheadandnecksquamouscellcarcinomadesigndevelopmentandplaceintherapy |